TheStreet upgraded shares of Mylan (NASDAQ:MYL) from a c rating to a b- rating in a research note published on Wednesday.

Other research analysts also recently issued research reports about the company. ValuEngine upgraded Mylan from a hold rating to a buy rating in a research note on Monday, October 2nd. BMO Capital Markets restated a buy rating and issued a $45.00 target price on shares of Mylan in a research note on Friday, September 29th. BTIG Research raised their target price on Mylan from $42.00 to $45.00 and gave the stock a buy rating in a research note on Wednesday, October 4th. Citigroup set a $42.00 target price on Mylan and gave the stock a buy rating in a research note on Wednesday, October 4th. Finally, Mizuho restated a buy rating and issued a $37.00 target price on shares of Mylan in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $44.19.

Shares of Mylan (MYL) traded up $0.22 during midday trading on Wednesday, reaching $46.73. The company’s stock had a trading volume of 7,887,043 shares, compared to its average volume of 6,458,200. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.25. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. The company has a market cap of $24,950.00, a P/E ratio of 28.15, a P/E/G ratio of 1.49 and a beta of 1.38.

Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the prior year, the business earned $1.38 EPS. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. equities research analysts predict that Mylan will post 4.56 EPS for the current fiscal year.

In other news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.69% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. raised its holdings in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares in the last quarter. BT Investment Management Ltd purchased a new position in shares of Mylan during the 3rd quarter valued at about $142,000. Doliver Capital Advisors LP purchased a new position in shares of Mylan during the 2nd quarter valued at about $201,000. Charter Trust Co. purchased a new position in shares of Mylan during the 4th quarter valued at about $226,000. Finally, Parametrica Management Ltd purchased a new position in shares of Mylan during the 3rd quarter valued at about $224,000. 74.90% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Mylan (MYL) Upgraded at TheStreet” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://theolympiareport.com/2018/01/19/mylan-myl-upgraded-at-thestreet.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.